BCR::ABL1 levels at first month after TKI discontinuation predict subsequent maintenance of treatment‐free remission: A study from the “GRUPPO TRIVENETO LMC”

We analyzed BCR::ABL1 expression at stop and in the first month after discontinuation in 168 chronic myeloid leukemia patients who stopped imatinib or 2nd generation tyrosine kinase inhibitors (2G‐TKIs) while in sustained deep molecular response. Patients were divided among those who maintained resp...

Descripción completa

Detalles Bibliográficos
Autores principales: Di Giusto, Sara, Toffoletti, Eleonora, Bonifacio, Massimiliano, Binotto, Gianni, Miggiano, Maria Cristina, Calistri, Elisabetta, Stulle, Manuela, Ermacora, Anna, Stella, Rossella, Scaffidi, Luigi, D'Amore, Fabio, Scotton, Giorgia, Griguolo, Davide, De Matteis, Giovanna, Bertorelle, Roberta, Krampera, Mauro, Semenzato, Gianpietro, Fanin, Renato, Damiani, Daniela, Tiribelli, Mario
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2022
Materias:
LETTERS TO THE EDITOR
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9939132/
https://www.ncbi.nlm.nih.gov/pubmed/36208021
http://dx.doi.org/10.1002/cam4.5158

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9939132/
https://www.ncbi.nlm.nih.gov/pubmed/36208021
http://dx.doi.org/10.1002/cam4.5158

Ejemplares similares